1. Home
  2. Labeler Index
  3. Aidarex Pharmaceuticals Llc
  4. 53217-369
  5. Product Images: Losartan Potassium

Product Images Losartan Potassium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Losartan Potassium NDC 53217-369 by Aidarex Pharmaceuticals Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Chemical Structure - losartan potassium 25mg 1

Chemical Structure - losartan potassium 25mg 1

Figure 1 - losartan potassium 25mg 2

Figure 1 - losartan potassium 25mg 2

This is a comparison between two medications: Atenolol and Losartan Potassium, with a table showing the percentage of patients who achieved the primary endpoint. The adjusted risk reduction is 13% with a p-value of 0.021. The graph shows the study month from 0 to 66, with data points at various intervals.*

Figure 2 - losartan potassium 25mg 3

Figure 2 - losartan potassium 25mg 3

Figure 3 - losartan potassium 25mg 4

Figure 3 - losartan potassium 25mg 4

The text describes the results of a study on the incidence of stroke in patients taking either Losartan or Atenolol. The study includes demographic subgroups such as age, gender, race, ISH, diabetes, and history of CVD. The primary endpoint of the study is a composite of fatal and non-fatal strokes. The text includes data on the number of events, rate, and hazard ratio for both medications. The results are displayed in a table with symbols proportional to sample size. The text is not readable due to formatting issues.*

Figure 4 - losartan potassium 25mg 5

Figure 4 - losartan potassium 25mg 5

This appears to be a presentation of the results of a clinical trial or study comparing the effectiveness of Losartan Potassium to a placebo. The data includes the percentage of patients with an event (which is not specified) and a graph that shows the percentage of patients over time. The study found a risk reduction of 16.1% with a p-value of 0.022. The graph shows a timeline of 48 months, divided into 4 equal sections (0-12, 12-24, 24-36, 36-48).*

53217-0369_LOSARTAN-POT_25MG - losartan potassium 25mg 6

53217-0369_LOSARTAN-POT_25MG - losartan potassium 25mg 6

Not available. The text is only a single character and a trademark symbol.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.